NewsRx

Search our medical news database

Acute Lymphoblastic Leukemia

Liposomal daunorubicin and cytarabine are effective as reinduction chemotherapy

Published in Drug Week, October 27th, 2006

Liposomal daunorubicin (DNX) and cytarabine are effective as reinduction chemotherapy for relapsed acute lymphoblastic leukaemia (ALL) despite expression of multidrug resistance (MDR)-related proteins.

According to recent research published in the European Journal of Haematology, "The treatment of relapsed adult ALL is frequently unsuccessful with current chemotherapy regimens, and often there is an overexpression of MDR-related proteins. Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that DNX (Daunoxome) is more toxic than DNR against ALL cell lines."

A....

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook